Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Combined With R-GemOx in Second-line DLBCL
NCT05786989Phase 4Unknown
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Chongqing University Cancer Hospital. Status: unknown.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05786989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786989.